PPI Sequencing Study

AstraZeneca

Status and phase: Completed; Phase 4

Conditions: Gastro-Oesophageal Reflux Disease

Treatments: Procedure: Pregnancy test if applicable; Procedure: Physical exam; Drug: Esomeprazole

Study type: Interventional

Funder types: Industry

Identifiers

NCT00384592

D9612L00104

Details and patient eligibility

About

The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a change in treatment.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Persisting symptoms of GORD despite previous treatment with a full dose proton pump inhibitor
• Informed consent
• Over 18 years of age

Exclusion criteria

• Current course of Proton Pump inhibitor treatment for more than 8 weeks prior to enrolment in the study;
• More than 1 other course of PPI treatment in the previous 12 month;
• Previous use of esomeprazole;
• Presence of alarm symptoms.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)